English
  • Capivasertib

    Capivasertib

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
    Capivasertib 1143532-39-1  Oct, 2026 Mar.10, 2030 estimated PV Completion – Aug, 2026

     

    [Indication] 

    In combination with fulvestrant, indicated for the treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

    inquirydetail
  • Crisaborole

    Crisaborole

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
    Crisaborole 906673-24-3  37356 Jun.29, 2029 Commercial Production

     

    [Indication] 

    It is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    inquirydetail
  • Canagliflozin

    Canagliflozin

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
    Canagliflozin 842133-18-0  36739 Jul.14, 2027 Commercial Production

     

    [Indication] 

    As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

    inquirydetail
  • Chlorothiazide

    Chlorothiazide

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status 
    Chlorothiazide 58-94-6

     

    [Indication] 

    1. For the management of hypertension, either as monotherapy or in combination with other antihypertensive agents.

    2. For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.

    3. For the treatment of central or nephrogenic diabetes insipidus.

    4. For the prevention of calcium-containing renal calculi by reducing urinary calcium excretion.

    inquirydetail
  • Captopril

    Captopril

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current status
    Captopril 62571-86-2  33888 Commercial Production

     

    [Indication] 

    1. For the treatment of hypertension.

    2. For the treatment of heart failure.

    3. For the treatment of patients who are medically stable following an acute myocardial infarction and who have left ventricular dysfunction.

    inquirydetail